modelCemiplimab
Extends from Pharmacolibrary.Drugs.ATC.L.L01FF06.
Information
| name: | Cemiplimab | |
| ATC code: | L01FF06 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 350 | mg |
| volume of distribution: | 4.41 | L |
| clearance: | 0.272 | L/day |
| other parameters in model implementation | ||
Cemiplimab is a human monoclonal antibody designed to bind to the programmed death-1 (PD-1) receptor and block its interaction with PD-L1 and PD-L2, thereby enhancing T-cell responses. It is approved for the treatment of cutaneous squamous cell carcinoma, non-small cell lung cancer, and basal cell carcinoma.
Pharmacokinetics
Pharmacokinetic model in adult cancer patients. Data represent population PK analysis of cemiplimab in patients with solid tumors.
References
Nguyen, JH, et al., & Al-Huniti, N (2022). Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer. CPT: pharmacometrics & systems pharmacology 11(11) 1458–1471. DOI:10.1002/psp4.12855 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36251220
Yang, F, et al., & DiCioccio, AT (2021). Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. Journal of pharmacokinetics and pharmacodynamics 48(4) 479–494. DOI:10.1007/s10928-021-09739-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/33728546
Paccaly, AJ, et al., & Rischin, D (2021). Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. Advances in therapy 38(5) 2365–2378. DOI:10.1007/s12325-021-01638-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33768419
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)